Tenderwize
Zurück zur Suche

Open House Pharmaceutical Rebate Contracts Timolol and Tafluprost (ATC S01ED70)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 03, 2027 · 371 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Tafluprost, ATC S01ED70

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

30 / 100

Risikofaktoren

The open-house contract can be automatically terminated if a conventional rebate contract for Timolol/Tafluprost comes...

Incorrect submission format (e.g., scanning without qualified signature, missing original copies) can delay contract st...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Non-exclusive discount agreements (Rabattverträge) for pharmaceutical products with active substances Timolol and Tafluprost (ATC S01ED70) under § 130a Abs. 8 SGB V.
Vollständige Zusammenfassung anzeigen

This is an open-house model for non-exclusive pharmaceutical rebate agreements (Rabattverträge) for the active substances Timolol and Tafluprost (ATC S01ED70) with AOK Bayern. Unlike a traditional tender, all eligible pharmaceutical enterprises can enter into identical, non-negotiable contracts during the window until 2027-09-03. The contracts run from 2025-11-01 to 2027-10-31. No award criteria apply; participation is open to all qualified pharmaceutical companies. The estimated contract value is not disclosed. The notice explicitly states this is not a procurement procedure under EU procurement law but an open-house model.

Risiken

The open-house contract can be automatically terminated if a conventional rebate contract for Timolol/Tafluprost comes...

Incorrect submission format (e.g., scanning without qualified signature, missing original copies) can delay contract st...

Wichtige Anforderungen

Technical

  • Only pharmaceutical enterprises (pharmazeutische Unternehmen) may participate.

Certifications

  • Documents must be submitted in German (or with certified German translation).

Administrative

  • Submission either in paper form (2 original copies signed by hand) or electronically with qualified electronic signature via the DTVP communication area.

Anforderungen können unvollständig sein.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Pharmaceutical Rebate Contracts Timolol and Tafluprost (ATC S01ED70)

Non-exclusive discount agreements for pharmaceutical products containing Timolol and Tafluprost (ATC S01ED70). Contract conclusion possible from 2025-11-01 to 2027-09-03. All contracts end on 2027-10-31. Subject to automatic termination if a nationwide or regional rebate contract (open procedure) for the same active substance takes effect.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Oct 2025 - Oct 2027

Kategorie

Pharmaceutical products

Frist

Deadline Sep 03, 2027

Vergabedetails

Veröffentlichungsdatum
14 Sep 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
599161-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30